Octagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

Octagon Capital Advisors LP grew its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,848,802 shares of the biopharmaceutical company's stock after acquiring an additional 585,101 shares during the period. Regulus Therapeutics comprises approximately 1.3% of Octagon Capital Advisors LP's holdings, making the stock its 24th largest position. Octagon Capital Advisors LP owned about 7.40% of Regulus Therapeutics worth $7,661,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC grew its position in Regulus Therapeutics by 69.7% in the 4th quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after acquiring an additional 900,743 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Regulus Therapeutics by 141.2% in the 4th quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock valued at $301,000 after buying an additional 111,485 shares during the period. Renaissance Technologies LLC grew its stake in Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock worth $185,000 after acquiring an additional 19,900 shares in the last quarter. Barclays PLC raised its stake in shares of Regulus Therapeutics by 13.9% during the fourth quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock valued at $152,000 after acquiring an additional 11,770 shares in the last quarter. Finally, PEAK6 LLC purchased a new stake in shares of Regulus Therapeutics in the fourth quarter valued at approximately $95,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock opened at $7.87 on Tuesday. Regulus Therapeutics Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $8.20. The firm has a 50 day moving average price of $2.89 and a 200 day moving average price of $1.93. The company has a market capitalization of $521.33 million, a PE ratio of -7.36 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. As a group, equities research analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group restated a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Jones Trading reaffirmed a "hold" rating and set a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Leerink Partners reissued a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

Want to see what other hedge funds are holding RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.